MENU
Aim higher

MELVAX

Development of an innovative immunotherapy against melanoma

We aim to generate a vaccine for malignant melanoma based on melanoma-associated endogenous retrovirus (MERV) antigens. Predicted and validated antigens are inserted into an influenza virus vector and the resulting vaccine (MelFlu) is tested in preclinical assays.
Acronym: 
MELVAX
Project ID: 
4 286
Ranking: 
12
Cut-off: 
1
Start date: 
01-01-2009
Project Duration: 
36months
Project costs: 
1 043 000.00€
Technological Area: 
BIOLOGICAL SCIENCES / TECHNOLOGIES
Market Area: 
Therapeutic services